Banco Santander announces third-quarter earnings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 29 2025
0mins
Should l Buy SAN?
Source: SeekingAlpha
Q3 Financial Performance: Banco Santander reported a Q3 GAAP EPS of €0.23, with net interest income of €10.35 billion, reflecting a 2% year-over-year increase. Profit attributable to the parent reached €3,504 million, marking a sixth consecutive quarterly record.
CET1 Ratio and Profit Growth: The CET1 ratio stood at 13.1% at the end of September 2025, slightly above the target range. Year-to-date, attributable profit increased by 11% to €10,337 million, driven by strong performances across revenue lines and controlled costs.
Impact of Argentina: Despite challenges in Argentina, profit growth remained resilient, with a 4% increase when excluding its impact. The bank's solid net fee income and lower provisions contributed to overall profitability.
Future Outlook: Banco Santander's strong profit growth across global businesses positions it well to meet its 2025 targets, supported by a solid increase in revenue and flat costs in real terms.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SAN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SAN
Wall Street analysts forecast SAN stock price to fall
2 Analyst Rating
0 Buy
1 Hold
1 Sell
Moderate Sell
Current: 11.190
Low
4.90
Averages
7.40
High
9.91
Current: 11.190
Low
4.90
Averages
7.40
High
9.91
About SAN
Banco Santander SA is a Spain-based company primarily engaged in retail and commercial banking. The Company operates through a model focused on personal and business banking, with significant operations in Europe, Latin America, and the United States. Its strategy emphasizes sustainable growth supported by customer centric operations, digital transformation, capital discipline, and a risk management framework. The Company leads an international network of subsidiaries offering the following services: retail banking, commercial banking, corporate and investment banking, wealth management, insurance, digital payments, capital markets services, advisory, risk‑management solutions, and structured finance.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
M&A Deal Closures Present Opportunities: Target Janus Henderson and Other Stocks.
- Merger and Acquisition Activity: The year has seen significant merger and acquisition activity, with many deals nearing closure.
- Stock Performance: Stocks of companies being acquired are expected to rise upon the completion of these deals.
See More
Opportunities Arise from Finalizing M&A Deals: Target Janus Henderson and Other Stocks.
- Merger and Acquisition Activity: The year has seen significant merger and acquisition activity, with many deals nearing closure.
- Stock Performance: Stocks of companies involved in these acquisitions are expected to rise once the deals are finalized.
See More
Santander Bank Under Investigation for Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating claims against Santander Bank and its executives for potential securities fraud and other unlawful business practices, aiming to protect investor rights and pursue legal accountability.
- Market Reaction: Following the collapse of UK mortgage provider Market Financial Solutions, Santander's American Depositary Shares (ADS) fell by 7.57% over two trading sessions, raising concerns about potential losses for the bank.
- Industry Impact: This incident has triggered warnings about broader risks in the private credit industry, undermining market confidence in Santander and potentially affecting its future financing capabilities and investor trust.
- Legal Context: Pomerantz LLP, a prominent securities class action law firm with over 85 years of history, is dedicated to advocating for victims of securities fraud, indicating that this case may lead to wider legal actions.
See More
DORAL RENEWABLES: MUFG LEADS DEBT SYNDICATE INCLUDING SANTANDER, HSBC, ALLY, AND IDB
Partnership Announcement: Doral Renewables has been appointed as the lead arranger for a financing deal involving multiple partners including Santander, HSBC, and others.
Debt Providers Involved: The arrangement includes a syndicate of debt providers, indicating a collaborative effort to support renewable energy projects.
See More
Dupixent Approved in Japan for Bullous Pemphigoid Treatment
- Clinical Trial Results: Dupixent (dupilumab) has been approved in Japan for the treatment of moderate-to-severe bullous pemphigoid (BP), based on the LIBERTY-BP-ADEPT Phase 2/3 trial results, which showed that 18% of Dupixent patients achieved sustained disease remission at Week 36, significantly higher than the 4% in the placebo group (p=0.0250), indicating its potential to improve patient quality of life.
- Safety Analysis: In the Dupixent group, 26% of patients experienced treatment-related adverse events (AEs), compared to 15% in the placebo group, with conjunctivitis being the most common AE at 4%, highlighting the need for careful safety management in clinical applications.
- Market Expansion: This approval marks the seventh indication for Dupixent in Japan, where it is also approved for atopic dermatitis, asthma, and other conditions, demonstrating its broad market applicability and further solidifying Regeneron and Sanofi's leadership in the immunotherapy space.
- Innovative Treatment Regimen: Dupixent is administered via subcutaneous injection every two weeks, in conjunction with standard oral corticosteroid (OCS) therapy, effectively controlling BP symptoms, which is expected to provide patients with more flexible treatment options, enhancing adherence and therapeutic outcomes.
See More
Dupixent Approved in Japan for Bullous Pemphigoid Treatment
- Approval in Japan: Dupixent (dupilumab) has been granted marketing authorization by Japan's Ministry of Health, Labour and Welfare as the first targeted therapy for adults with moderate-to-severe bullous pemphigoid (BP), marking a significant advancement in the dermatology sector.
- Clinical Trial Results: In the LIBERTY-BP-ADEPT study, 18% of Dupixent patients achieved sustained remission at Week 36, compared to only 4% in the placebo group (p=0.0250), demonstrating its superior efficacy in treating BP.
- Safety Data: Among Dupixent patients, 26% reported treatment-related adverse events, with conjunctivitis being the most common at 4%, indicating a need for ongoing monitoring of the risk-benefit profile.
- Market Potential: This approval represents the seventh indication for Dupixent in Japan, which is expected to further enhance its acceptance in over 60 countries globally, strengthening the company's competitive position in the immunotherapy market.
See More
M&A Deal Closures Present Opportunities: Target Janus Henderson and Other Stocks.
- Merger and Acquisition Activity: The year has seen significant merger and acquisition activity, with many deals nearing closure.
- Stock Performance: Stocks of companies being acquired are expected to rise upon the completion of these deals.
See More
Opportunities Arise from Finalizing M&A Deals: Target Janus Henderson and Other Stocks.
- Merger and Acquisition Activity: The year has seen significant merger and acquisition activity, with many deals nearing closure.
- Stock Performance: Stocks of companies involved in these acquisitions are expected to rise once the deals are finalized.
See More
Santander Bank Under Investigation for Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating claims against Santander Bank and its executives for potential securities fraud and other unlawful business practices, aiming to protect investor rights and pursue legal accountability.
- Market Reaction: Following the collapse of UK mortgage provider Market Financial Solutions, Santander's American Depositary Shares (ADS) fell by 7.57% over two trading sessions, raising concerns about potential losses for the bank.
- Industry Impact: This incident has triggered warnings about broader risks in the private credit industry, undermining market confidence in Santander and potentially affecting its future financing capabilities and investor trust.
- Legal Context: Pomerantz LLP, a prominent securities class action law firm with over 85 years of history, is dedicated to advocating for victims of securities fraud, indicating that this case may lead to wider legal actions.
See More
DORAL RENEWABLES: MUFG LEADS DEBT SYNDICATE INCLUDING SANTANDER, HSBC, ALLY, AND IDB
Partnership Announcement: Doral Renewables has been appointed as the lead arranger for a financing deal involving multiple partners including Santander, HSBC, and others.
Debt Providers Involved: The arrangement includes a syndicate of debt providers, indicating a collaborative effort to support renewable energy projects.
See More
Dupixent Approved in Japan for Bullous Pemphigoid Treatment
- Clinical Trial Results: Dupixent (dupilumab) has been approved in Japan for the treatment of moderate-to-severe bullous pemphigoid (BP), based on the LIBERTY-BP-ADEPT Phase 2/3 trial results, which showed that 18% of Dupixent patients achieved sustained disease remission at Week 36, significantly higher than the 4% in the placebo group (p=0.0250), indicating its potential to improve patient quality of life.
- Safety Analysis: In the Dupixent group, 26% of patients experienced treatment-related adverse events (AEs), compared to 15% in the placebo group, with conjunctivitis being the most common AE at 4%, highlighting the need for careful safety management in clinical applications.
- Market Expansion: This approval marks the seventh indication for Dupixent in Japan, where it is also approved for atopic dermatitis, asthma, and other conditions, demonstrating its broad market applicability and further solidifying Regeneron and Sanofi's leadership in the immunotherapy space.
- Innovative Treatment Regimen: Dupixent is administered via subcutaneous injection every two weeks, in conjunction with standard oral corticosteroid (OCS) therapy, effectively controlling BP symptoms, which is expected to provide patients with more flexible treatment options, enhancing adherence and therapeutic outcomes.
See More
Dupixent Approved in Japan for Bullous Pemphigoid Treatment
- Approval in Japan: Dupixent (dupilumab) has been granted marketing authorization by Japan's Ministry of Health, Labour and Welfare as the first targeted therapy for adults with moderate-to-severe bullous pemphigoid (BP), marking a significant advancement in the dermatology sector.
- Clinical Trial Results: In the LIBERTY-BP-ADEPT study, 18% of Dupixent patients achieved sustained remission at Week 36, compared to only 4% in the placebo group (p=0.0250), demonstrating its superior efficacy in treating BP.
- Safety Data: Among Dupixent patients, 26% reported treatment-related adverse events, with conjunctivitis being the most common at 4%, indicating a need for ongoing monitoring of the risk-benefit profile.
- Market Potential: This approval represents the seventh indication for Dupixent in Japan, which is expected to further enhance its acceptance in over 60 countries globally, strengthening the company's competitive position in the immunotherapy market.
See More
